313 related articles for article (PubMed ID: 30408543)
41. Environmental toxicants, incidence of degenerative diseases, and therapies from the epigenetic point of view.
Hodjat M; Rahmani S; Khan F; Niaz K; Navaei-Nigjeh M; Mohammadi Nejad S; Abdollahi M
Arch Toxicol; 2017 Jul; 91(7):2577-2597. PubMed ID: 28516248
[TBL] [Abstract][Full Text] [Related]
42. Coordinated Actions of MicroRNAs with other Epigenetic Factors Regulate Skeletal Muscle Development and Adaptation.
Bianchi M; Renzini A; Adamo S; Moresi V
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28420141
[TBL] [Abstract][Full Text] [Related]
43. Epigenetic cancer therapy: Proof of concept and remaining challenges.
Mund C; Lyko F
Bioessays; 2010 Nov; 32(11):949-57. PubMed ID: 21154865
[TBL] [Abstract][Full Text] [Related]
44. Epigenetics and miRNAs in human cancer.
Fabbri M; Calin GA
Adv Genet; 2010; 70():87-99. PubMed ID: 20920746
[TBL] [Abstract][Full Text] [Related]
45. Histone deacetylation meets miRNA: epigenetics and post-transcriptional regulation in cancer and chronic diseases.
Swierczynski S; Klieser E; Illig R; Alinger-Scharinger B; Kiesslich T; Neureiter D
Expert Opin Biol Ther; 2015 May; 15(5):651-64. PubMed ID: 25766312
[TBL] [Abstract][Full Text] [Related]
46. Epigenetic modifications of triterpenoid ursolic acid in activating Nrf2 and blocking cellular transformation of mouse epidermal cells.
Kim H; Ramirez CN; Su ZY; Kong AN
J Nutr Biochem; 2016 Jul; 33():54-62. PubMed ID: 27260468
[TBL] [Abstract][Full Text] [Related]
47. Targeting epigenetic mechanisms: potential of natural products in cancer chemoprevention.
Hauser AT; Jung M
Planta Med; 2008 Oct; 74(13):1593-601. PubMed ID: 18704881
[TBL] [Abstract][Full Text] [Related]
48. Epigenetic control using natural products and synthetic molecules.
Suzuki T; Miyata N
Curr Med Chem; 2006; 13(8):935-58. PubMed ID: 16611076
[TBL] [Abstract][Full Text] [Related]
49. Epigenetic regulation of microRNA expression in colorectal cancer.
Bandres E; Agirre X; Bitarte N; Ramirez N; Zarate R; Roman-Gomez J; Prosper F; Garcia-Foncillas J
Int J Cancer; 2009 Dec; 125(11):2737-43. PubMed ID: 19521961
[TBL] [Abstract][Full Text] [Related]
50. Targeting epigenetic enzymes for drug discovery.
Copeland RA; Olhava EJ; Scott MP
Curr Opin Chem Biol; 2010 Aug; 14(4):505-10. PubMed ID: 20621549
[TBL] [Abstract][Full Text] [Related]
51. Epigenetically Active Drugs Inhibiting DNA Methylation and Histone Deacetylation.
Chistiakov DA; Myasoedova VA; Orekhov AN; Bobryshev YV
Curr Pharm Des; 2017; 23(8):1167-1174. PubMed ID: 27774908
[TBL] [Abstract][Full Text] [Related]
52. The epigenetic feedback loop between DNA methylation and microRNAs in fibrotic disease with an emphasis on DNA methyltransferases.
Sun X; He Y; Huang C; Ma TT; Li J
Cell Signal; 2013 Sep; 25(9):1870-6. PubMed ID: 23707521
[TBL] [Abstract][Full Text] [Related]
53. Epigenetic Modifications in Neurological Diseases: Natural Products as Epigenetic Modulators a Treatment Strategy.
Gangisetty O; Murugan S
Adv Neurobiol; 2016; 12():1-25. PubMed ID: 27651245
[TBL] [Abstract][Full Text] [Related]
54. DNA methyltransferase inhibitors in cancer: a chemical and therapeutic patent overview and selected clinical studies.
Fahy J; Jeltsch A; Arimondo PB
Expert Opin Ther Pat; 2012 Dec; 22(12):1427-42. PubMed ID: 23033952
[TBL] [Abstract][Full Text] [Related]
55. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
56. Interplay between microRNAs and the epigenetic machinery: an intricate network.
Iorio MV; Piovan C; Croce CM
Biochim Biophys Acta; 2010; 1799(10-12):694-701. PubMed ID: 20493980
[TBL] [Abstract][Full Text] [Related]
57. Epigenetic Modifications and Therapy in Multiple Sclerosis.
Aslani S; Jafari N; Javan MR; Karami J; Ahmadi M; Jafarnejad M
Neuromolecular Med; 2017 Mar; 19(1):11-23. PubMed ID: 27382982
[TBL] [Abstract][Full Text] [Related]
58. [Epigenetic mechanisms and alcohol use disorders: a potential therapeutic target].
Legastelois R; Jeanblanc J; Vilpoux C; Bourguet E; Naassila M
Biol Aujourdhui; 2017; 211(1):83-91. PubMed ID: 28682229
[TBL] [Abstract][Full Text] [Related]
59. DNA Methyltransferases Inhibitors from Natural Sources.
Zwergel C; Valente S; Mai A
Curr Top Med Chem; 2016; 16(7):680-96. PubMed ID: 26303417
[TBL] [Abstract][Full Text] [Related]
60. Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors.
Schneider-Stock R; Ocker M
IDrugs; 2007 Aug; 10(8):557-61. PubMed ID: 17665331
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
